Re-Use of Established Drugs for Anti-Metastatic Indications
AbstractMost patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Entschladen, F.; Thyssen, D.A.; Drell, D.W. Re-Use of Established Drugs for Anti-Metastatic Indications. Cells 2016, 5, 2.
Entschladen F, Thyssen DA, Drell DW. Re-Use of Established Drugs for Anti-Metastatic Indications. Cells. 2016; 5(1):2.Chicago/Turabian Style
Entschladen, Frank; Thyssen, Dane A.; Drell, David W. 2016. "Re-Use of Established Drugs for Anti-Metastatic Indications." Cells 5, no. 1: 2.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.